Mylan shareholders have overwhelmingly approved the generic drug maker’s proposed merger with Upjohn, Mylan announced Tuesday.
Approximately 99.6% of votes cast were voted in favor of the transaction.
Pending regulatory approvals, the merger is expected to be completed in the fourth quarter, Mylan said.
Mylan, which is run from executive offices in Cecil, had expected the deal to be completed by now, but in March announced a delay due to expected delays in the regulatory approval process because of the pandemic.
Upjohn, based in China, is the generic and off-patent brand name drug unit of Pfizer Inc.
The newly combined company is to be called Viatris.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.
First Published: June 30, 2020, 4:34 p.m.
